Recently, I noticed that oncology companies are in the news for raising new financing or even announcing IPO’s, and wondered if that was an anomaly after the credit shutdown following the Wall St crisis. In general, my perception was …
Excerpt from:
The Biotech IPO isn't dead yet! - Pharma Strategy Blog
0 responses so far ↓
There are no comments yet...Kick things off by filling out the form below.
You must log in to post a comment.